JPRN-UMIN000047500已完成未知
A randomized, double-blind, parallel-group study of rosemary materials - A randomized, double-blind, parallel-group study of rosemary materials
Clinical Creative Co., Ltd0 个研究点目标入组 44 人开始时间: 2022年5月12日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 44
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 60years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Those who are taking medication that may affect the test results. 2.Those who may show allergic symptoms to the test food. 3.Those who have participated in other clinical trials within one month prior to obtaining consent or are currently participating in other clinical trials. 4. Critical illness [heart failure, myocardial infarction, myocarditis, etc.] (however, this does not apply if it is determined that a pacemaker or other device will not affect the study), liver disease [hepatic failure symptoms (fulminant hepatitis), cirrhosis, liver tumor], renal disease [nephrotic syndrome, renal failure (acute and chronic), uremia, hydronephrosis], etc. Complications and general health problems. 5.Patients with severe anemia 6.Subjects for whom, in the judgment of the study investigator or subinvestigator, there is a possibility of increased risk to the subject or inadequate data to be obtained by conducting the study. 7.Those who work at night or in rotating shifts 8.Those who regularly drink energy drinks 9.Those using health foods, supplements, and medications that affect stress, cognitive function 10.Those who consume rosemary supplements or a diet with large amounts of rosemary.
研究者
相似试验
进行中（未招募）
不适用
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-InhibitorAdult Rheumatoid Arthritis (RA)MedDRA version: 13.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2010-023587-40-GRF. Hoffmann-La Roche Ltd.700
进行中（未招募）
不适用
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-InhibitorAdult Rheumatoid Arthritis (RA)MedDRA version: 14.0Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2010-023587-40-DEF. Hoffmann-La Roche Ltd.700
进行中（未招募）
不适用
A Study of RoActemra/Actemra (Tocilizumab) Given Subcutaneously in Combination With Traditional DMARDs in Patients With Moderate to Severe Active Rheumatoid ArthritisAdult Rheumatoid Arthritis (RA)MedDRA version: 14.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2010-019912-18-BGF. Hoffmann-La Roche Ltd.600
撤回
3 期
A randomized, double-blind, parallel-group study of the reduction of signs and symptoms during treatment with tocilizumab versus adalimumab, both in combination with MTX, in patients with moderate to severe active rheumatoid arthritis and an inadequate response to treatment with only one TNF inhibitor.RA1000381610023213rheumatoid arthritisNL-OMON36590Roche Nederland B.V.15
进行中（未招募）
1 期
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One TNF-InhibitorAdult Rheumatoid Arthritis (RA)MedDRA version: 14.0Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2010-023587-40-DKF. Hoffmann-La Roche Ltd.700